Genmab Reports Q1 Revenue of $896M
Reports Q1 revenue $896M, consensus $901.1M. "We made tangible progress in the first quarter as we continue to integrate Merus and advance our late-stage portfolio - EPKINLY, Rina-S and petosemtamab. Across the business, our focus remained on disciplined execution, progressing these programs toward key readouts and preparing for potential launches to have an impact on more patients," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
